Coherus BioSciences
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 306
- Market Cap
- $160.1M
- Website
- http://www.coherus.com
- Introduction
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and Coherus COMPLETE. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.
Clinical Trials
28
Trial Phases
4 Phases
Drug Approvals
4
Clinical Trials
Distribution across different clinical trial phases (27 trials with phase data)• Click on a phase to view related trials
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- Coherus Biosciences, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT06679985
- Locations
- 🇺🇸
The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solovev Research Institute (OSUCCC - James), Columbus, Ohio, United States
🇺🇸Beverly Hills Cancer Center, Beverly Hills, California, United States
🇺🇸City of Hope, Duarte, California, United States
A Study of CHS-114 in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
- Conditions
- Metastatic Solid TumorAdvanced Solid Tumor
- Interventions
- First Posted Date
- 2024-10-24
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- Coherus Biosciences, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT06657144
- Locations
- 🇺🇸
The University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Ochsner Health, New Orleans, Louisiana, United States
🇺🇸Prisma Health Cancer Institute, Greenville, South Carolina, United States
A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer
- Conditions
- Nasopharyngeal Cancer Recurrent
- Interventions
- First Posted Date
- 2024-06-13
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- Coherus Biosciences, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT06457503
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸University of California, Irvine, Irvine, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors
- Conditions
- Advanced or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Coherus Biosciences, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT06389526
Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors
- Conditions
- Advanced Solid TumorNon-Small Cell Lung CancerHepatocellular Carcinoma
- Interventions
- Drug: CHS-006 (anti-TIGIT)
- First Posted Date
- 2023-03-07
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Coherus Biosciences, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT05757492
- Locations
- 🇺🇸
University of Florida Health Cancer Center, Orlando, Florida, United States
🇺🇸Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Renown Institute for Cancer, Reno, Nevada, United States
- Prev
- 1
- 2
- 3
- 4
- Next
News
STORM Therapeutics Initiates First-in-Class RNA Modification Therapy Combination Trial with Checkpoint Inhibitor
STORM Therapeutics has dosed the first patient in a Phase 1b/2 combination study evaluating STC-15, a METTL3 inhibitor, with LOQTORZI (toripalimab) for multiple cancer types.
Coherus BioSciences Completes $558.4 Million UDENYCA Divestiture to Intas, Pivots to Oncology Focus
Coherus BioSciences has completed the divestiture of its UDENYCA pegfilgrastim franchise to Intas Pharmaceuticals in a deal valued at up to $558.4 million, receiving $483.4 million upfront with potential for $75 million in milestone payments.
Coherus Reports Promising Phase 1 Data for CHS-114 in Head and Neck Cancer, Showing Potential to Overcome PD-1 Resistance
Coherus BioSciences' selective anti-CCR8 antibody CHS-114 demonstrated clinical efficacy in combination with toripalimab in head and neck squamous cell carcinoma, achieving a confirmed partial response in a heavily pretreated PD-1 refractory patient.
FDA Delays Toripalimab Review for Nasopharyngeal Carcinoma Due to Pending Manufacturing Site Inspection
The FDA has not issued an action letter for toripalimab's Biologics License Application by the December 23, 2022 PDUFA date, pending required manufacturing facility inspection in China.
FDA Tightens Requirements for China-Developed Drugs, Mandates Multi-Regional Trials
The FDA has rejected multiple China-developed drugs, including Hutchmed's surufatinib and Eli Lilly's sintilimab, citing concerns over single-country clinical trial data.
Coherus BioSciences' Liver Cancer Triplet Therapy Shows Promise in Phase 2 Study
Coherus BioSciences' novel triplet therapy combining casdozo, atezolizumab, and bevacizumab demonstrates significant efficacy in treating metastatic hepatocellular carcinoma during Phase 2 trials.
INOVIO Advances DNA Medicine Pipeline with Focus on INO-3107 BLA Submission for RRP
INOVIO plans to submit a Biologics License Application (BLA) to the FDA for INO-3107 by mid-2025, seeking priority review for recurrent respiratory papillomatosis.
Coherus' Casdozokitug Shows Promising Results in Liver Cancer Phase 2 Trial
Coherus BioSciences presented final Phase 2 data for casdozokitug combined with atezolizumab and bevacizumab in patients with unresectable or metastatic hepatocellular carcinoma.
Global Biosimilars Market Set to Triple to $114 Billion by 2031, Driven by Patent Expirations and Cost Advantages
The global biosimilars market is projected to grow from $36.01 billion in 2024 to $114.02 billion by 2031, representing a robust CAGR of 17.9%, fueled by increasing demand for cost-effective biologics.
China's Biopharmaceutical Sector Achieves Record Technology Exports and FDA Approvals
• Chinese pharmaceutical companies saw technology exports nearly double in 2023, reaching a record high of 80 cases, signaling growing global influence. • FDA approved Junshi Biosciences' Toripalimab for nasopharyngeal cancer and Bio-Thera Solutions' Avitinib, highlighting recognition of Chinese therapies. • Multinational firms like Merck and Johnson & Johnson have invested billions in Chinese biotech, developing drugs like Carvykti for multiple myeloma. • China leads in CAR-T clinical trials, accounting for 51% globally, but Korean bio companies face stagnation in technology export amounts.